S65487 (VOB560), a prodrug of S55746, induced apoptosis in BCL2-dependent hematological cell lines and displayed synergy when combined with MCL1 inhibitors in AML patient-derived xenografts.337 Additionally, S65487 was potent in pre-clinical models resistant to venetoclax, including those that harbored BCL2 mutations.337 S65487 is being assessed clinically in combination with a MCL1 inhibitor for the treatment of R/R AML, MM or NHL (NCT04702425) or in combination with azacitidine in patients with untreated AML (NCT04742101), but both studies are currently not recruiting. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.